Evidence map›Paper›PMID 12134947›Full record

ArticlePharmaceutical research2002

Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.

Fuxing Tang, Ronald T Borchardt

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 27 citations in OpenAlex.

  1. Cyclic Opioid Peptides.Current medicinal chemistry · 2016
    Review
  2. Expression of intestinal transporter genes in beagle dogs.Experimental and therapeutic medicine · 2013
    Article
  3. Cyclization-activated prodrugs.Molecules (Basel, Switzerland) · 2007
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Fuxing TangDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence 66047, USA.
Ronald T Borchardt
University of Kansas · US

Funding

CYCLIC PRODRUGS OF OPIOID PEPTIDESR01DA009315 · NIDA · UNIVERSITY OF KANSAS LAWRENCE · PI BORCHARDT, RONALD T · 1995 to 2007
$1.7M
NIDA NIH HHS DA09315
6 · The paper itself

Abstract

purposeTo elucidate the efflux transporter(s) responsible for restricting the permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE (AD) through Caco-2 cell monolayers.

methodsThe cellular permeation characteristics of AD were investigated using Caco-2 cells, Madin-Darby canine kidney wild-type II cells (MDCK-WT), MDCK cells transfected with the human MDR1 gene (MDCK-MDR1), and MDCK cells transfected with the human MRP2 gene (MDCK-MRP2). These cells were grown as monolayers onto microporous membranes. The disappearance of AD from the donor side and its appearance on the receiver side were monitored by high-performance liquid chromatography. The substrate activity of AD for P-glycoprotein (P-gp) was determined using GF120918, a known P-gp specific inhibitor. The substrate activity of AD for MRP2 was determined by using cyclosporin A, a known MRP2 and P-gp inhibitor.

resultsIn Caco-2 cells, the ratio of the apparent permeability coefficients (Papp) of AD flux measured in the basolateral (BL) to apical (AP) direction vs. the flux in the AP-to-BL direction (Papp BL-to-AP/ Papp AP-to-BL) was 99. In the presence of 2 microM GF120918 or 25 microM cyclosporin A. the Papp BL-to-AP/Papp AP-to-BL ratio was decreased to 11. In MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells, the Papp BL-to-AP/Papp AP-to-BL ratios of AD were 4.7, 10, and 5.8, respectively. A mixture of GF120918 (2 microM) and cyclosporin A (25 microM) decreased the Papp BL-to-AP/Papp AP-to-BL ratios of AD in MDCK-WT, MDCK-MDR1, and MDCK-MRP2 cells to 1.2,1.8, and 2.3, respectively.

conclusionsThese data suggest that AD is a much better substrate for P-gp than MRP2 and that the restricted permeation of this cyclic prodrug in Caco-2 cells and in the intestinal mucosa probably is due primarily to its substrate activity for P-gp.

Indexed as

Mitochondrial ProteinsSaccharomyces cerevisiae ProteinsAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1Caco-2 CellsCell LineDogsEnkephalin, Leucine-2-AlanineGenes, MDRHumansIntestinal MucosaMultidrug Resistance-Associated Protein 2Opioid PeptidesPermeabilityProdrugsRibosomal ProteinsABCC2 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 1Enkephalin, Leucine-2-AlanineMitochondrial ProteinsMRP2 protein, S cerevisiaeMultidrug Resistance-Associated Protein 2Opioid PeptidesProdrugsRibosomal ProteinsSaccharomyces cerevisiae Proteins

Identifiers

PMID12134947
OpenAlexW76807496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.